BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 25723392)

  • 1. Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinoma.
    Wang WM; Zhao ZL; Ma SR; Yu GT; Liu B; Zhang L; Zhang WF; Kulkarni AB; Sun ZJ; Zhao YF
    PLoS One; 2015; 10(2):e0119723. PubMed ID: 25723392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
    Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
    Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
    Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of endothelial cell network formation in vitro by molecular signaling of head and neck squamous cell carcinoma (HNSCC) exposed to cetuximab.
    Jouan-Hureaux V; Boura C; Merlin JL; Faivre B
    Microvasc Res; 2012 Mar; 83(2):131-7. PubMed ID: 21820450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model.
    Gustafsson H; Kale A; Dasu A; Lund A; Edqvist PH; Roberg K
    Cell Biochem Biophys; 2017 Dec; 75(3-4):299-309. PubMed ID: 28756482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
    Chen MC; Lee CF; Huang WH; Chou TC
    Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.
    Gyanchandani R; Sano D; Ortega Alves MV; Klein JD; Knapick BA; Oh S; Myers JN; Kim S
    Oral Oncol; 2013 Aug; 49(8):761-70. PubMed ID: 23623402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase in gene dosage is a mechanism of HIF-1alpha constitutive expression in head and neck squamous cell carcinomas.
    Secades P; Rodrigo JP; Hermsen M; Alvarez C; Suarez C; Chiara MD
    Genes Chromosomes Cancer; 2009 May; 48(5):441-54. PubMed ID: 19235921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia induces TFE3 expression in head and neck squamous cell carcinoma.
    Sun ZJ; Yu GT; Huang CF; Bu LL; Liu JF; Ma SR; Zhang WF; Liu B; Zhang L
    Oncotarget; 2016 Mar; 7(10):11651-63. PubMed ID: 26872381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms.
    Pore N; Jiang Z; Gupta A; Cerniglia G; Kao GD; Maity A
    Cancer Res; 2006 Mar; 66(6):3197-204. PubMed ID: 16540671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA interference-mediated downregulation of hypoxia-inducible factor-1α inhibits angiogenesis and survival of oral squamous cell carcinoma in vitro and in vivo.
    Zhou H; Fei W; Bai Y; Zhu S; Luo E; Chen K; Hu J
    Eur J Cancer Prev; 2012 May; 21(3):289-99. PubMed ID: 22113109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
    Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
    J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer.
    Liu JF; Deng WW; Chen L; Li YC; Wu L; Ma SR; Zhang WF; Bu LL; Sun ZJ
    Mol Carcinog; 2018 Mar; 57(3):429-439. PubMed ID: 29215754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-induced ROS promotes mitochondrial fission and cisplatin chemosensitivity via HIF-1α/Mff regulation in head and neck squamous cell carcinoma.
    Wu K; Mao YY; Chen Q; Zhang B; Zhang S; Wu HJ; Li Y
    Cell Oncol (Dordr); 2021 Oct; 44(5):1167-1181. PubMed ID: 34460078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
    Ricker JL; Chen Z; Yang XP; Pribluda VS; Swartz GM; Van Waes C
    Clin Cancer Res; 2004 Dec; 10(24):8665-73. PubMed ID: 15623651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor biology in head and neck cancer.
    Kalyankrishna S; Grandis JR
    J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
    Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
    PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ascochlorin inhibits growth factor-induced HIF-1α activation and tumor-angiogenesis through the suppression of EGFR/ERK/p70S6K signaling pathway in human cervical carcinoma cells.
    Jeong JH; Jeong YJ; Cho HJ; Shin JM; Kang JH; Park KK; Park YY; Chung IK; Chang HW; Magae J
    J Cell Biochem; 2012 Apr; 113(4):1302-13. PubMed ID: 22109717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.
    Lee JG; Wu R
    Neoplasia; 2015 Feb; 17(2):190-200. PubMed ID: 25748238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.